Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by Meeder Advisory Services Inc.

Meeder Advisory Services Inc. boosted its position in Moderna, Inc. (NASDAQ:MRNA) by 78.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,447 shares of the company’s stock after purchasing an additional 1,516 shares during the quarter. Meeder Advisory Services Inc.’s holdings in Moderna were worth $409,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MRNA. Cedar Wealth Management LLC increased its holdings in shares of Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after purchasing an additional 90 shares during the last quarter. Commerzbank Aktiengesellschaft FI grew its holdings in Moderna by 1.7% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after buying an additional 93 shares in the last quarter. CVA Family Office LLC increased its stake in shares of Moderna by 21.6% in the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after acquiring an additional 96 shares during the last quarter. Claro Advisors LLC raised its holdings in shares of Moderna by 2.0% during the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after acquiring an additional 108 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Moderna by 32.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after acquiring an additional 116 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

MRNA has been the topic of several recent analyst reports. Evercore ISI reiterated an “in-line” rating and issued a $120.00 target price on shares of Moderna in a report on Thursday, June 27th. Barclays decreased their price objective on Moderna from $168.00 to $155.00 and set an “overweight” rating on the stock in a report on Friday, August 2nd. Royal Bank of Canada cut their target price on Moderna from $90.00 to $75.00 and set a “sector perform” rating for the company in a research note on Friday. Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and decreased their price target for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. Finally, Bank of America reduced their price objective on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a report on Friday. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $108.53.

Insider Buying and Selling

In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $127.22, for a total value of $1,908,300.00. Following the sale, the director now directly owns 2,284,015 shares in the company, valued at $290,572,388.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 93,158 shares of company stock worth $11,167,312. Company insiders own 15.70% of the company’s stock.

Moderna Stock Down 2.0 %

Moderna stock opened at $68.28 on Monday. The firm has a market capitalization of $26.17 billion, a P/E ratio of -4.36 and a beta of 1.67. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $170.47. The stock’s fifty day simple moving average is $95.06 and its 200-day simple moving average is $111.89.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. Moderna’s revenue was down 29.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($3.62) EPS. As a group, equities analysts expect that Moderna, Inc. will post -9.52 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.